Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 6, Number 1, 2001

Tolerance of radiotherapy (3D-CRT) and androgen ablation for patients with prostate cancer

Milecki P, Stryczyńska G, Stachowski T, Kwias Z, Matecka-Nowak M.


Purpose: evaluation acute tolerance of combined treatment (XRT and HT). Material/methods: Between April 1999 and September 2000, 22 patients with prostate cancer (T1-T3NXM0) were treated with 3D-CRT and HT. Median age of patients was 68 years.EBRT was administered daily fraction of 1.8Gy,total dose 70.2Gy. Planning target volume (PTV) was defined as clinical target volume CTV(prostate and seminal vesicles) with 10mm margins around prostate except posterior margin where 5mm were used to decrease risk of rectum morbidity.Acute toxicities were evaluated using RTOG scoring scale. Median follow-up was 11 months. Results: Acute effects in gastrointestinal tract (GI) noted were; rectal discomfort and mild diarrhea. Acute genitourinary (GU) symptoms included urgency, nocturia and dysuria. GI toxicity was observed in 75 % of patients (grade 0 and 1), and 25% of patients (grade 2). GU toxicities were as follow: grade 0 and 1 -80% of patients) and grade 2 -(20% of patients). No grade 3 or 4 GI and GU toxicities were observed. Conclusions: Preliminary results of treatment with 3D-CRT suggested that such modality is well tolerated. HT did not exacerbate radiation toxicity.

Signature: Rep Pract Oncol Radiother, 2001; 6(1) : 34-34

« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.